John Quisel | BiotechTV

top of page

2 days ago

ASH 2024: Disc Medicine's CEO shares an update on three programs, including an oral presentation for an anti-anemia antibody for patients with myelofibrosis and potentially beyond in the future

John Quisel shares an update on ASH data for DISC-0974, bitopertin, and DISC-3405.

Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program

Jul 1

Company News

Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program

John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light....

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh